Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Multiple drugs

Various toxicities, drug resistance and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Leite CA, et al. Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report. Frontiers in Oncology 13: no pagination, Jan 2023. Available from: URL: https://dx.doi.org/10.3389/fonc.2023.1264231 Leite CA, et al. Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report. Frontiers in Oncology 13: no pagination, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​3389/​fonc.​2023.​1264231
Metadaten
Titel
Multiple drugs
Various toxicities, drug resistance and lack of efficacy
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52475-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Vedolizumab

Case report

Multiple drugs

Case report

Multiple drugs